Comparison of in situ and extraction-based methods for the detection of MET amplifications in solid tumors

In EGFR-treatment naive NSCLC patients, high-level MET amplification is detected in approximately 2–3% and is considered as adverse prognostic factor. Currently, clinical trials with two different inhibitors, capmatinib and tepotinib, are under way both defining different inclusion criteria regardin...

Descripción completa

Detalles Bibliográficos
Autores principales: Heydt, Carina, Becher, Ann-Kathrin, Wagener-Ryczek, Svenja, Ball, Markus, Schultheis, Anne M., Schallenberg, Simon, Rüsseler, Vanessa, Büttner, Reinhard, Merkelbach-Bruse, Sabine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Research Network of Computational and Structural Biotechnology 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6861603/
https://www.ncbi.nlm.nih.gov/pubmed/31762957
http://dx.doi.org/10.1016/j.csbj.2019.09.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6861603/
https://www.ncbi.nlm.nih.gov/pubmed/31762957
http://dx.doi.org/10.1016/j.csbj.2019.09.003

Ejemplares similares